Glucagonoma is an endocrine disorder that occurs when cells in the pancreas produce too much of the hormone glucagon. This disorder can cause a range of symptoms, including weight loss, skin problems, and even diabetes. It's important to understand all you need to know about glucagonoma if you or someone you love are struggling with this health condition. In this blog post, we'll cover the causes, treatments, and how to manage it. With some knowledge and understanding of this disorder, you can be better equipped to tackle it head-on.
Glucagonoma is a rare type of neuroendocrine tumor that arises from the alpha cells of the pancreas. These tumors secrete high levels of glucagon, which leads to a condition called necrolytic migratory erythema (NME). NME is characterized by a rash that typically starts on the face and trunk and spreads to the extremities. Glucagonomas can also lead to weight loss, anemia, diabetes, and diarrhea. Treatment for glucagonoma typically involves surgery to remove the tumor followed by radiation therapy or chemotherapy.
There are a few possible causes of glucagonoma, though the exact cause is unknown. One theory is that it may be due to a genetic mutation. Other possible causes include:
-An autoimmune reaction
-A viral infection
-Exposure to certain chemicals or toxins
There are a few ways to diagnose glucagonoma. One way is through a fasting blood test. This is because when you fast, your body breaks down stored glycogen for energy, which raises blood glucose levels. If you have glucagonoma, your fasting blood sugar will be higher than normal.
Another way to diagnose glucagonoma is through a C-peptide test. C-peptide is a byproduct of insulin production. People with diabetes usually have lower than normal levels of C-peptide because their bodies aren't producing enough insulin. If you have glucagonoma, your C-peptide levels will be higher than normal because your body is overproducing insulin.
Lastly, imaging tests such as CT scans or MRI can be used to look for tumors on the pancreas. However, these tests aren't always accurate and may not show anything even if you have a tumor.
If you have been diagnosed with glucagonoma, your treatment plan will likely involve a combination of medication, surgery, and lifestyle changes.
Medication: The first line of treatment for glucagonoma is usually octreotide (Sandostatin), a drug that helps to control the release of insulin and other hormones. Octreotide is taken as an injection under the skin or into a muscle. Other medications that may be used to treat glucagonoma include somatostatin analogues, such as lanreotide (Somatuline Depot) and pasireotide (Signifor), and dopamine agonists, such as cabergoline (Dostinex).
Surgery: If octreotide does not effectively control hormone levels or if the tumor is large and causing symptoms, surgery may be recommended. The goal of surgery is to remove the tumor and any surrounding tissue that may be affected. Surgery may be done using traditional open techniques or laparoscopic surgery, which involves making small incisions in the abdomen and using long instruments to remove the tumor.
Lifestyle changes: In addition to medication and surgery, making lifestyle changes can help to manage the symptoms of glucagonoma. These changes may include eating smaller meals more often, avoiding fatty foods and alcohol, quitting smoking, and getting regular exercise.
Glucagonoma is a rare tumor that affects the pancreas. It can cause various symptoms and there are several possible treatments available depending on how severe the condition is. If you suspect that you or someone you know may be affected by this condition, it’s important to seek medical advice as soon as possible so that an accurate diagnosis can be made and appropriate treatment prescribed. By understanding the causes, treatments and management options surrounding glucagonoma, we have hopefully provided those suffering with some useful information and guidance in managing their condition better.
1.
There has been a recent decrease in the risk of a recurrence of colorectal cancer in stage I to III cases.
2.
In NSCLC, subcutaneous Lazertinib + Amivantamab Dosing Is Not Worse Than IV Dosing.
3.
Recurrent UTIs impact eGFR in children with vesicoureteral reflux
4.
Month-Long Wait Times Caused by US Physician Shortage.
5.
Pharyngoesophageal junction cancer is not a good candidate for endoscopically assisted transoral surgery.
1.
A Closer Look at Poorly Differentiated Carcinoma: Uncovering its Complexities
2.
The Importance of Early Detection in Angiosarcoma: A Story of Survival
3.
Leukemia in Focus: Tools, Trials, and Therapy Strategies for Modern Medical Practice
4.
New Research Advances in the Treatment of Multiple Myeloma and Plasmacytoma
5.
Managing KRAS Inhibitor Toxicities: Focus on Rash and Beyond
1.
International Lung Cancer Congress®
2.
Genito-Urinary Oncology Summit 2026
3.
Future NRG Oncology Meeting
4.
ISMB 2026 (Intelligent Systems for Molecular Biology)
5.
Annual International Congress on the Future of Breast Cancer East
1.
Incidence of Lung Cancer- An Overview to Understand ALK Rearranged NSCLC
2.
Molecular Contrast: EGFR Axon 19 vs. Exon 21 Mutations - Part III
3.
Untangling The Best Treatment Approaches For ALK Positive Lung Cancer - Part III
4.
An Eagles View - Evidence-based Discussion on Iron Deficiency Anemia- Panel Discussion IV
5.
Untangling The Best Treatment Approaches For ALK Positive Lung Cancer - Part V
© Copyright 2025 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation